Akebia Therapeutics (AKBA) Return on Capital Employed Growth (3y) (2017 - 2026)
Akebia Therapeutics (AKBA) Return on Capital Employed Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1,301.00 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 353.00 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 480.00 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1,342.00 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 2,112.00 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 626.00 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1,809.00 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1,788.00 |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | 2,298.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,298.00 |
| Dec 31, 2025 | 4,118.00 |
| Sep 30, 2025 | 5,607.00 |
| Jun 30, 2025 | 4,921.00 |
| Mar 31, 2025 | 8,089.00 |
| Dec 31, 2024 | 4,884.00 |
| Sep 30, 2024 | 4,459.00 |
| Jun 30, 2024 | 3,272.00 |
| Mar 31, 2024 | 6,113.00 |
| Dec 31, 2023 | 4,619.00 |
| Sep 30, 2023 | 4,104.00 |
| Jun 30, 2023 | 1,593.00 |
| Mar 31, 2023 | 2,739.00 |
| Dec 31, 2022 | 1,993.00 |
| Sep 30, 2022 | -3.00 |
| Jun 30, 2022 | -1,108.00 |
| Mar 31, 2022 | -6,254.00 |
| Dec 31, 2021 | -4,579.00 |
| Sep 30, 2021 | -3,638.00 |
| Jun 30, 2021 | -3,686.00 |